Compare UCAR & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UCAR | PTHL |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.8M |
| IPO Year | 2023 | 2024 |
| Metric | UCAR | PTHL |
|---|---|---|
| Price | $1.85 | $0.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 76.8K |
| Earning Date | 10-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,816,075.00 | $448,196.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.22 | N/A |
| 52 Week Low | $1.74 | $0.47 |
| 52 Week High | $9.43 | $32.00 |
| Indicator | UCAR | PTHL |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 41.04 |
| Support Level | $1.77 | $0.59 |
| Resistance Level | $1.95 | $0.63 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 7.55 | 36.70 |
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.